{"mainPropery":{"diseaseId":7360,"diseaseName":"Polyarteritis nodosa","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7360/polyarteritis-nodosa","synonyms":["PAN","Periarteritis","Polyarteritis"],"synonyms-with-source":[{"name":"PAN"},{"name":"Periarteritis","source":"NORD"},{"name":"Polyarteritis","source":"NORD"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"767"},{"identifierType":"UMLS","identifierId":"C0031036"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases"},{"diseaseTypeId":33,"diseaseTypeName":"RDCRN"}],"organizations":[{"resourceID":117,"resourceName":"Vasculitis Foundation","abbreviation":"","address1":"P.O. Box 28660","address2":"","address3":"","address4":"","address5":"","city":"Kansas City","state":"MO","zip":"64188","country":"United States","phone":"+1-816-436-8211 ","tty":"","tollFree":"1-800-277-9474","fax":"+1-816-656-3838","email":"https://www.vasculitisfoundation.org/contact-us-2/","url":"https://www.vasculitisfoundation.org/","freeText":""},{"resourceID":933,"resourceName":"American Autoimmune Related Diseases Association","abbreviation":"AARDA","address1":"19176 Hall Road, Suite 130","address2":"","address3":"","address4":"","address5":"","city":"Clinton Township","state":"MI","zip":"48038","country":"United States","phone":"586-776-3900","tty":"","tollFree":"800-598-4668","fax":"586-776-3903","email":"aarda@aarda.org","url":"https://www.aarda.org/","freeText":""},{"resourceID":2387,"resourceName":"Vasculitis Foundation Canada","abbreviation":"","address1":"","address2":"","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"","tty":"","tollFree":"1-877-572-9474","fax":"","email":"","url":"http://www.vasculitis.ca/","freeText":"Contact form: http://www.vasculitis.ca/?page_id=30"}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=%28Polyarteritis%5BTitle%5D+AND+nodosa%5BTitle%5D%29+AND+%28%22loattrfree+full+text%22%5Bsb%5D+AND+hasabstract%5Btext%5D+AND+%22humans%22%5BMeSH+Terms%5D+AND+English%5Blang%5D+AND+%28Meta%2DAnalysis%5Bptyp%5D+OR+Review%5Bptyp%5D%29%29' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Polyarteritis nodosa. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Polyarteritis+nodosa%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Polyarteritis nodosa. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":633,"resourceId":1357,"resourceName":"All Star Vasculitis Patient Symposium","descriptionText":"<a href='http://www.vasculitisfoundation.org/node/2998 ' target='_blank'>All Star Vasculitis Patient Symposium<br /></a>July 30, 2010 - August 1, 2010<br /><strong>Location:</strong> Westin Long Beach Hotel in Long Beach, California<br /><strong>Description: </strong>Topics will cover all the types of vasculitis and will concentrate on the advances in medical treatments, research, and quality of life of patients. The meeting attracts vasculitis patients, family members, and medical vasculitis experts in the world.","resourceClassificationName":"News & Events","resourceClassificationSectionName":"Other Conferences"},{"id":739,"resourceId":1429,"resourceName":"Johns Hopkins Vasculitis Center","descriptionText":"The <a href='https://www.hopkinsvasculitis.org/types-vasculitis/polyarteritis-nodosa/' target='_blank'>Johns Hopkins Vasculitis Center</a> has a web page on polyarteritis nodosa.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1376,"resourceId":2026,"resourceName":"The Cleveland Clinic","descriptionText":"The <a href='http://my.clevelandclinic.org/health/diseases_conditions/hic_Polyarteritis_Nodosa' target='_blank'>The Cleveland Clinic</a> Web site has an&nbsp;information page on Polyarteritis nodosa. Click on the Cleveland Clinic link to view this page.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1377,"resourceId":2027,"resourceName":"RDCRN - Vasculitis Clinical Research Consortium (VCRC)","descriptionText":"The <a href='https://www.rarediseasesnetwork.org/cms/vcrc' target='_blank'>Vasculitis Clinical Research Consortium</a> (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis. The VCRC has a contact registry for patients who wish to be contacted about clinical research opportunities and updates on the progress of the VCRC research projects.<br /><br />For more information on the registry see: <a href='https://www.rarediseasesnetwork.org/cms/vcrc/About-Us' target='_blank'>https://www.rarediseasesnetwork.org/cms/vcrc/About-Us</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/666/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001438.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/330717-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=767' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1538,"resourceId":2169,"resourceName":"MeSH®","descriptionText":"<a href='https://meshb.nlm.nih.gov/record/ui?ui=D010488' target='_blank'>MeSH®</a> (Medical Subject Headings) is a terminology tool used by the National Library of Medicine. Click on the link to view information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1542,"resourceId":2170,"resourceName":"RePORTER","descriptionText":"The <a href='http://projectreporter.nih.gov/project_info_description.cfm?aid=7680704' target='_blank'>Research Portfolio Online Reporting Tool (RePORT)</a> provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research.  Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the \"Text Search\" box.  Then click \"Submit Query\".","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='https://www.merckmanuals.com/home/bone,-joint,-and-muscle-disorders/vasculitic-disorders/polyarteritis-nodosa-pan' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1700,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The&nbsp;<a href='http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/polyarteritis-nodosa-pan?qt=Polyarteritis%20nodosa&alt=sh' target='_blank'>Merck Manual</a> for health care professionals provides information on&nbsp;Polyarteritis nodosa.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:615688' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2232,"resourceId":117,"resourceName":"Vasculitis Foundation","descriptionText":"The&nbsp;<a href='http://www.vasculitisfoundation.org/education/forms/polyarteritis-nodosa/' target='_blank'>Vasculitis Foundation</a> provides information about&nbsp;Polyarteritis nodosa.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2233,"resourceId":117,"resourceName":"Vasculitis Foundation","descriptionText":"The&nbsp;<a href='http://www.vasculitisfoundation.org/map-2/' target='_blank'>Vasculitis Foundation</a> has a \"Find a Physician\" map on its website.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":2781,"resourceId":4265,"resourceName":"Autoimmune Registry","descriptionText":"The <a href='http://www.autoimmuneregistry.org/' target='_blank'>Autoimmune Registry</a> supports research for Polyarteritis nodosa by collecting information about patients with this and other autoimmune diseases. You can join the registry to share your information with researchers and receive updates about participating in new research studies.&nbsp;<a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries.</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":2944,"questionText":"What is polyarteritis nodosa?","answerText":"<strong>Polyarteritis nodosa</strong>&nbsp;(PAN) is a blood vessel disease characterized by inflammation of small and medium-sized arteries (<a href=\"http://www.mayoclinic.org/diseases-conditions/vasculitis/basics/definition/con-20026049\" target=\"_blank\">vasculitis</a>), preventing them from bringing oxygen and food to organs.[12538][1956] Most cases occur in the 4th or 5th decade of life, although it can occur at any age.[12539] PAN most commonly affects vessels related to the skin, joints, peripheral nerves, gastrointestinal tract, heart, eyes, and kidneys.[12539][12540] Symptoms are caused by damage to affected organs and may include&nbsp;fever, fatigue, weakness, loss of appetite, weight loss, muscle and joint aches, rashes, numbness, and abdominal pain. The underlying cause of PAN is unknown. Treatment involves medicines to suppress inflammation and the immune system, including&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">steroids</a>.[1956]","dateModified":"2016-11-07T00:00:00"},"basicQuestions":[{"questionId":11288,"questionText":"What causes polyarteritis nodosa?","answerText":"The exact cause of polyarteritis nodosa (PAN) is not known, and in most cases, no predisposing cause has been found (it is idiopathic). Many scientists believe that it is an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">autoimmune disease</a>. Research has suggested that an abnormal immune response to an initial infection may trigger the development of PAN.[12538]&nbsp;However, the reasons that many smaller arteries and capillaries are spared is not understood.[12544]<br />\r\n<br />\r\nHepatitis B virus (HBV), hepatitis C, and hairy cell leukemia have been associated with some cases of PAN. In one report from France, HBV accounted for a third of the cases of PAN. HBV-related PAN typically occurs within four months after the onset of HBV infection.[12544] PAN has also been seen in drug abusers (particularly those using amphetamines). It has also appeared to occur as an allergic reaction to some drugs and vaccines.[12538]<br />\r\n<br />\r\nThe specific symptoms of PAN are due to ischemia or infarction of tissues and organs. Thickening of the walls of affected vessels causes narrowing of the inside of the vessels, reducing blood flow and predisposing to blood clots in affected vessels.[12544]","dateModified":"2016-11-07T12:14:00","resourceClassificationName":"Cause","references":[{"referenceId":12538,"authors":"","articleTitle":"Polyarteritis nodosa","bookWebsiteJournalTitle":"NORD","date":"2008","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/polyarteritis-nodosa/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12544,"authors":"Peter A Merkel","articleTitle":"Clinical manifestations and diagnosis of polyarteritis nodosa in adults","bookWebsiteJournalTitle":"UpToDate","date":"October, 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":2946,"questionText":"How might polyarteritis nodosa be treated?","answerText":"There is no cure for polyarteritis nodosa (PAN), but the disease and its symptoms can be managed.&nbsp;The goal of treatment is to prevent disease progression and further organ damage.[12541] The exact treatment depends on the severity in each person.[12542] While many people do well with treatment, relapses can occur.[12541]<br />\r\n<br />\r\nWhen the cause of PAN is unknown (idiopathic), treatment involves corticosteroids and immunosuppressive medications.[12541] If there are no&nbsp;serious neurologic, renal, gastrointestinal, or heart symptoms, corticosteroids may initially be sufficient. For severe disease with these symptoms, <a href=\"http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/cyclophosphamide\" target=\"_blank\">cyclophosphamide</a> may also be used. Hypertension should be treated aggressively.[12542]<br />\r\n<br />\r\nWhen PAN is related to hepatitis B, treatment often involves steroids, anti-viral medications and sometimes plasma exchange (also called <a href=\"http://emedicine.medscape.com/article/1895577-overview?pa=7VurjvXHiZ0Q0xXCdS30D3R92l3yLswqlW71SzcgcngMLj27VHjdUw3s6lHIQuE643mU9jD%2B1DtnxY47OmyybA%3D%3D\" target=\"_blank\">plasmapheresis</a>).[12541]","dateModified":"2016-11-07T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12541,"authors":"","articleTitle":"Polyarteritis Nodosa","bookWebsiteJournalTitle":"Vasculitis Foundation","date":"2016","volume":"","pages":"","url":"http://www.vasculitisfoundation.org/education/forms/polyarteritis-nodosa/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12542,"authors":"","articleTitle":"Polyarteritis Nodosa (PAN)","bookWebsiteJournalTitle":"Merck Manual","date":"February, 2016","volume":"","pages":"","url":"http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/polyarteritis-nodosa-pan?qt=Polyarteritis%20nodosa&alt=sh","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":5893,"questionText":"What is the average life expectancy for individuals with polyarteritis nodosa?","answerText":"We could not find a description of the average life expectancy for individuals with polyarteritis nodosa.&nbsp; However, one study examined the overall mortality of a group of individuals with this condition.&nbsp; Mortality is a measure of the proportion of individuals in a group who die in a given time period.&nbsp; Of 348 individual with polyarteritis nodosa, approximately 20% had died within 5 years of initial diagnosis and treatment;&nbsp;approximately 32% had died within 10 years.&nbsp; Only a third of these deaths was directly&nbsp;caused by&nbsp;severe symptoms of polyarteritis nodosa.&nbsp; Factors which increased the risk of death included being older than 65 years, being recently diagnosed with high blood pressure (<a href=\"http://www.nlm.nih.gov/medlineplus/highbloodpressure.html\" target=\"_blank\">hypertension</a>), or having <a href=\"http://www.merriam-webster.com/medlineplus/gastrointestinal\" target=\"_blank\">gastrointestinal</a> symptoms that required surgery at the time of diagnosis (for example, abdominal pain, internal bleeding, <a href=\"http://www.nlm.nih.gov/medlineplus/pancreatitis.html\" target=\"_blank\">pancreatitis</a>, <a href=\"http://www.mayoclinic.com/health/cholecystitis/DS01153/METHOD=print&amp;DSECTION=all\" target=\"_blank\">cholecystitis</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/appendicitis.html\" target=\"_blank\">appendicitis</a>).[4889]","dateModified":"2012-01-18T06:47:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4889,"authors":"Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L; French Vasculitis Study Group","articleTitle":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database","bookWebsiteJournalTitle":"Arthritis and Rheumatism","date":"2010","volume":"62","pages":"616-626","url":"http://www.ncbi.nlm.nih.gov/pubmed/20112401","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":11290,"questionText":"How rare is polyarteritis nodosa?","answerText":"Polyarteritis nodosa (PAN) is a rare disease, with an incidence of about 3 to 4.5 cases per 100,000 people annually in the United States (about 1 in 22,000 to 1 in 33,000 people). Internationally, the annual estimated incidence of PAN ranges from 1.6 cases per million in south Sweden, for example, to 30.7 cases per million adults in Paris.[12543]<br />\r\n<br />\r\nPAN affects men more frequently than women. While it has been diagnosed in people of every age, it predominantly occurs in people between the ages of 45-65 years.[12543]","dateModified":"2016-11-07T12:15:00","resourceClassificationName":"Statistics","references":[{"referenceId":12543,"authors":"Dana Jacobs-Kosmin","articleTitle":"Polyarteritis Nodosa","bookWebsiteJournalTitle":"Medscape Reference","date":"January 12, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/330717-overview","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":59195,"abbreviatedInquiry":"How does this disease affect the gastrointestinal tract? What are the causes of this disease? Does it have anything to do with collagen? How rare is it?","caseQuestions":[{"questionId":11287,"questionText":"How might polyarteritis nodosa affect the gastrointestinal tract?","answerText":"Gastrointestinal (GI) involvement in polyarteritis nodosa (PAN) usually manifests as nonspecific symptoms  such as abdominal pain, nausea, and/or vomiting, with or without obvious GI bleeding (blood in the stools).[12543] Abdominal discomfort may be intermittent or continuous and may be most prominent after meals.[12544] Weight loss may follow due to decreased food intake and/or malabsorption.[12544]<br />\r\n<br />\r\nIn some cases, symptoms may depend on the exact location of the affected part of the GI tract. For example, vasculitis affecting the liver or gallbladder may cause right upper quadrant pain.[12542]<br />\r\n<br />\r\nMore serious complications of PAN involving the GI tract are rare but include bowel infarction (obstruction of blood) and <a href=\"https://medlineplus.gov/ency/article/000235.htm\" target=\"_blank\">perforation</a>, <a href=\"http://www.mayoclinic.org/diseases-conditions/cholecystitis/basics/definition/con-20034277\" target=\"_blank\">cholecystitis</a>, hepatic infarction, or pancreatic infarction.[12543]","dateModified":"2016-11-07T12:13:00","references":[{"referenceId":12542,"authors":"","articleTitle":"Polyarteritis Nodosa (PAN)","bookWebsiteJournalTitle":"Merck Manual","date":"February, 2016","volume":"","pages":"","url":"http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/polyarteritis-nodosa-pan?qt=Polyarteritis%20nodosa&alt=sh","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12543,"authors":"Dana Jacobs-Kosmin","articleTitle":"Polyarteritis Nodosa","bookWebsiteJournalTitle":"Medscape Reference","date":"January 12, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/330717-overview","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12544,"authors":"Peter A Merkel","articleTitle":"Clinical manifestations and diagnosis of polyarteritis nodosa in adults","bookWebsiteJournalTitle":"UpToDate","date":"October, 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":11288,"questionText":"What causes polyarteritis nodosa?","answerText":"The exact cause of polyarteritis nodosa (PAN) is not known, and in most cases, no predisposing cause has been found (it is idiopathic). Many scientists believe that it is an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">autoimmune disease</a>. Research has suggested that an abnormal immune response to an initial infection may trigger the development of PAN.[12538]&nbsp;However, the reasons that many smaller arteries and capillaries are spared is not understood.[12544]<br />\r\n<br />\r\nHepatitis B virus (HBV), hepatitis C, and hairy cell leukemia have been associated with some cases of PAN. In one report from France, HBV accounted for a third of the cases of PAN. HBV-related PAN typically occurs within four months after the onset of HBV infection.[12544] PAN has also been seen in drug abusers (particularly those using amphetamines). It has also appeared to occur as an allergic reaction to some drugs and vaccines.[12538]<br />\r\n<br />\r\nThe specific symptoms of PAN are due to ischemia or infarction of tissues and organs. Thickening of the walls of affected vessels causes narrowing of the inside of the vessels, reducing blood flow and predisposing to blood clots in affected vessels.[12544]","dateModified":"2016-11-07T12:14:00","resourceClassificationName":"Cause","references":[{"referenceId":12538,"authors":"","articleTitle":"Polyarteritis nodosa","bookWebsiteJournalTitle":"NORD","date":"2008","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/polyarteritis-nodosa/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12544,"authors":"Peter A Merkel","articleTitle":"Clinical manifestations and diagnosis of polyarteritis nodosa in adults","bookWebsiteJournalTitle":"UpToDate","date":"October, 2016","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"Waltham, MA","publisher":"UpToDate"}]},{"questionId":11289,"questionText":"Does&nbsp;polyarteritis nodosa have anything to do with collagen?","answerText":"Polyarteritis nodosa (PAN) has sometimes been referred to as a \"collagen disease\" or a \"collagen vascular disease.\"[12545][12547][12546] Historically, the term \"collagen vascular disease\" has been used to describe similar autoimmune disorders associated with inflammation of the connective tissues (including the arteries). Connective tissues are made up of collagen fibers, in addition to other materials. However, now that we have names for these individual disorders, the term is not used as frequently for these disorders.[12545]&nbsp;Additionally, the term \"collagen disease\" has more recently been used to describe diseases caused by <em>defects</em>&nbsp;in collagen (eg, <a href=\"https://rarediseases.info.nih.gov/diseases/6322/ehlers-danlos-syndrome\" target=\"_blank\">Ehlers-Danlos syndrome</a>), rather than diseases affecting structures made of collagen. To our knowledge, there is not currently evidence that PAN is due to a defect in collagen. Besides PAN, other disorders that have been considered collagen vascular diseases include <a href=\"https://rarediseases.info.nih.gov/diseases/9518/ankylosing-spondylitis\" target=\"_blank\">ankylosing spondylitis</a>, <a href=\"https://rarediseases.info.nih.gov/diseases/6263/dermatomyositis\" target=\"_blank\">dermatomyositis</a>, <a href=\"https://www.psoriasis.org/psoriatic-arthritis\" target=\"_blank\">psoriatic arthritis</a>, <a href=\"http://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/home/ovc-20197388\" target=\"_blank\">rheumatoid arthritis</a>, <a href=\"https://rarediseases.info.nih.gov/diseases/10308/scleroderma\" target=\"_blank\">scleroderma</a>, and <a href=\"https://rarediseases.info.nih.gov/diseases/10253/systemic-lupus-erythematosus\" target=\"_blank\">systemic lupus erythematosus</a>.[12547]","dateModified":"2016-11-07T12:14:00","references":[{"referenceId":12545,"authors":"","articleTitle":"Collagen vascular disease","bookWebsiteJournalTitle":"MedlinePlus","date":"January 20, 2015","volume":"","pages":"","url":"https://medlineplus.gov/ency/article/001223.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12546,"authors":"Nakamura T, et al","articleTitle":"Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria","bookWebsiteJournalTitle":"Arch Dermatol Res","date":"January, 2009","volume":"301(1)","pages":"117-121","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12547,"authors":"","articleTitle":"Collagen vascular disease","bookWebsiteJournalTitle":"University of Iowa Children's Hospital","date":"2016","volume":"","pages":"","url":"https://www.uichildrens.org/Adam/?/HIE%20Multimedia/1/001223","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":11290,"questionText":"How rare is polyarteritis nodosa?","answerText":"Polyarteritis nodosa (PAN) is a rare disease, with an incidence of about 3 to 4.5 cases per 100,000 people annually in the United States (about 1 in 22,000 to 1 in 33,000 people). Internationally, the annual estimated incidence of PAN ranges from 1.6 cases per million in south Sweden, for example, to 30.7 cases per million adults in Paris.[12543]<br />\r\n<br />\r\nPAN affects men more frequently than women. While it has been diagnosed in people of every age, it predominantly occurs in people between the ages of 45-65 years.[12543]","dateModified":"2016-11-07T12:15:00","resourceClassificationName":"Statistics","references":[{"referenceId":12543,"authors":"Dana Jacobs-Kosmin","articleTitle":"Polyarteritis Nodosa","bookWebsiteJournalTitle":"Medscape Reference","date":"January 12, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/330717-overview","authors2":"","placeOfPublication":"","publisher":""}]}]},{"caseId":33550,"abbreviatedInquiry":"I&nbsp;was diagnosed with polyarteritis nodosa last year and had to have my leg amputated.&nbsp; What is the estimated rate of recurrence for this condition?&nbsp; What is the life expectancy for people with this condition?","caseQuestions":[{"questionId":5892,"questionText":"How often does polyarteritis nodosa return (relapse) after initial treatment?","answerText":"One study of 348 individuals with polyarteritis nodosa found that approximately 22% of people experienced a return of symptoms (a <a href=\"http://www.merriam-webster.com/medlineplus/relapse\" target=_blank>relapse</a>) within 5.5 years of their initial diagnosis and treatment.&nbsp; Individuals in whom the polyarteritis nodosa was associated with a <a href=\"http://www.nlm.nih.gov/medlineplus/hepatitisb.html\" target=_blank>hepatitis B virus (HBV)</a> infection were less likely to have a relapse than those in whom the polyarteritis nodosa was not associated with HBV.&nbsp; Another factor that seemed to increase the chance of a relapse included having&nbsp;skin (<a href=\"http://www.merriam-webster.com/medlineplus/cutaneous\" target=_blank>cutaneous</a>) findings at diagnosis, such as nodules, or&nbsp;purple or bluish patches in the skin (<a href=\"http://www.merriam-webster.com/medlineplus/purpura\" target=_blank>purpura</a>&nbsp;or <a href=\"http://www.merriam-webster.com/medlineplus/livedo\" target=_blank>livedo</a>, respectively).[4889]","dateModified":"2012-01-18T06:47:00","resourceClassificationName":"Treatment","references":[{"referenceId":4889,"authors":"Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L; French Vasculitis Study Group","articleTitle":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database","bookWebsiteJournalTitle":"Arthritis and Rheumatism","date":"2010","volume":"62","pages":"616-626","url":"http://www.ncbi.nlm.nih.gov/pubmed/20112401","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":5893,"questionText":"What is the average life expectancy for individuals with polyarteritis nodosa?","answerText":"We could not find a description of the average life expectancy for individuals with polyarteritis nodosa.&nbsp; However, one study examined the overall mortality of a group of individuals with this condition.&nbsp; Mortality is a measure of the proportion of individuals in a group who die in a given time period.&nbsp; Of 348 individual with polyarteritis nodosa, approximately 20% had died within 5 years of initial diagnosis and treatment;&nbsp;approximately 32% had died within 10 years.&nbsp; Only a third of these deaths was directly&nbsp;caused by&nbsp;severe symptoms of polyarteritis nodosa.&nbsp; Factors which increased the risk of death included being older than 65 years, being recently diagnosed with high blood pressure (<a href=\"http://www.nlm.nih.gov/medlineplus/highbloodpressure.html\" target=\"_blank\">hypertension</a>), or having <a href=\"http://www.merriam-webster.com/medlineplus/gastrointestinal\" target=\"_blank\">gastrointestinal</a> symptoms that required surgery at the time of diagnosis (for example, abdominal pain, internal bleeding, <a href=\"http://www.nlm.nih.gov/medlineplus/pancreatitis.html\" target=\"_blank\">pancreatitis</a>, <a href=\"http://www.mayoclinic.com/health/cholecystitis/DS01153/METHOD=print&amp;DSECTION=all\" target=\"_blank\">cholecystitis</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/appendicitis.html\" target=\"_blank\">appendicitis</a>).[4889]","dateModified":"2012-01-18T06:47:00","resourceClassificationName":"Prognosis","references":[{"referenceId":4889,"authors":"Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L; French Vasculitis Study Group","articleTitle":"Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database","bookWebsiteJournalTitle":"Arthritis and Rheumatism","date":"2010","volume":"62","pages":"616-626","url":"http://www.ncbi.nlm.nih.gov/pubmed/20112401","authors2":"","placeOfPublication":"","publisher":""}]}]},{"caseId":25414,"abbreviatedInquiry":"How can I find information on treatment for polyarteritis nodosa? Are there any dietary supplements or other alternative therapies that have been used to treat polyarteritis nodosa?","caseQuestions":[{"questionId":2946,"questionText":"How might polyarteritis nodosa be treated?","answerText":"There is no cure for polyarteritis nodosa (PAN), but the disease and its symptoms can be managed.&nbsp;The goal of treatment is to prevent disease progression and further organ damage.[12541] The exact treatment depends on the severity in each person.[12542] While many people do well with treatment, relapses can occur.[12541]<br />\r\n<br />\r\nWhen the cause of PAN is unknown (idiopathic), treatment involves corticosteroids and immunosuppressive medications.[12541] If there are no&nbsp;serious neurologic, renal, gastrointestinal, or heart symptoms, corticosteroids may initially be sufficient. For severe disease with these symptoms, <a href=\"http://www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/cyclophosphamide\" target=\"_blank\">cyclophosphamide</a> may also be used. Hypertension should be treated aggressively.[12542]<br />\r\n<br />\r\nWhen PAN is related to hepatitis B, treatment often involves steroids, anti-viral medications and sometimes plasma exchange (also called <a href=\"http://emedicine.medscape.com/article/1895577-overview?pa=7VurjvXHiZ0Q0xXCdS30D3R92l3yLswqlW71SzcgcngMLj27VHjdUw3s6lHIQuE643mU9jD%2B1DtnxY47OmyybA%3D%3D\" target=\"_blank\">plasmapheresis</a>).[12541]","dateModified":"2016-11-07T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12541,"authors":"","articleTitle":"Polyarteritis Nodosa","bookWebsiteJournalTitle":"Vasculitis Foundation","date":"2016","volume":"","pages":"","url":"http://www.vasculitisfoundation.org/education/forms/polyarteritis-nodosa/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12542,"authors":"","articleTitle":"Polyarteritis Nodosa (PAN)","bookWebsiteJournalTitle":"Merck Manual","date":"February, 2016","volume":"","pages":"","url":"http://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/vasculitis/polyarteritis-nodosa-pan?qt=Polyarteritis%20nodosa&alt=sh","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2947,"questionText":"Are there dietary supplements or other alternative therapies that have been used to treat polyarteritis nodosa?","answerText":"It is always helpful to maintain a <a href=\"http://www.nlm.nih.gov/medlineplus/healthyliving.html\" target=_blank>healthy diet&nbsp;and lifestyle</a>; however, we are not aware of any alternative therapies or supplements of particular benefit for treatment of polyarteritis nodosa. We recommend that you talk with your healthcare provider further regarding your treatment options.","dateModified":"2012-01-16T09:33:00","references":[]},{"questionId":2948,"questionText":"Are there clinical trials investigating new therapies for treatment of polyarteritis nodosa?&nbsp;&nbsp;&nbsp;&nbsp;","answerText":"The <a href=\"http://rarediseasesnetwork.epi.usf.edu/vcrc/\" target=_blank>Vasculitis Clinical Research Consortium</a> (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis, including polyarteritis nodosa. The VCRC has a <a href=\"http://rarediseasesnetwork.epi.usf.edu/vcrc/takeaction/registrymenu.htm\" target=_blank>contact registry</a> for patients who wish to&nbsp;be contacted about clinical research opportunities and updates on the progress of the VCRC research projects.<br><br>Vasculitis Clinical Research Consortium (VCRC)<br>Carol King, MA<br>Project Manager<br>715 Albany Street, E-5<br>Boston, MA 02118<br>Telephone: 617-414-2505<br>Fax: 617-414-2510<br>E-mail: <a href=\"mailto:caking@bu.edu\">acaking@bu.edu</a><br><br>The U.S. National Institutes of Health, through the National Library of Medicine, developed <a href=\"http://www.clinicaltrials.gov/\" target=_blank>ClinicalTrials.gov</a> to provide patients, family members, and members of the public with current information on clinical research studies. Currently, clinical trials are identified as enrolling individuals with <a href=\"http://clinicaltrials.gov/ct2/results?term=polyarteritis+nodosa&amp;amp;recr=Open\" target=_blank>polyarteritis nodosa</a>.&nbsp;After you click on a study, review its \"eligibility\" criteria to determine its appropriateness. Use the study’s contact information to learn more. Check this site often for regular updates. \r\n<p></p>\r\n<p>You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling the toll-free number 1-800-411-1222 to speak with a specialist, who can help you determine if you are eligible for any clinical trials.&nbsp;&nbsp; </font></p>\r\n<p>If you are interested in enrolling in a clinical trial, you can find helpful general information on clinical trials at the following ClinicalTrials.gov Web page.<br><a href=\"http://clinicaltrials.gov/ct2/info/understand\" target=_blank>http://clinicaltrials.gov/ct2/info/understand</a></p>\r\n<p>Resources on many charitable or special-fare flights to research and treatment sites and low-cost hospitality accommodations for outpatients and family members, as well as ambulance services, are listed on the Web site of the Office of Rare Diseases Research (ORDR), part of the National Institutes of Health.<br><a href=\"http://rarediseases.info.nih.gov/Resources.aspx?PageID=8\" target=_blank>http://rarediseases.info.nih.gov/Resources.aspx?PageID=8</a></p>","dateModified":"2012-01-16T09:33:00","references":[]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":10011,"phenoTypeName":"Abnormality of the kidney","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":7919,"phenoTypeName":"Arthralgia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14045,"phenoTypeName":"Elevated C-reactive protein level","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3980,"phenoTypeName":"Myalgia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":1243,"phenoTypeName":"Polyneuritis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13419,"phenoTypeName":"Abdominal pain","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14096,"phenoTypeName":"Abnormality of the gastrointestinal tract","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10292,"phenoTypeName":"Cutis marmorata","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11167,"phenoTypeName":"Erythema","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6027,"phenoTypeName":"Hypertension","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13398,"phenoTypeName":"Morphological central nervous system abnormality","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3852,"phenoTypeName":"Pericarditis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14615,"phenoTypeName":"Raynaud phenomenon","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5585,"phenoTypeName":"Sensory axonal neuropathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":967,"phenoTypeName":"Skin ulcer","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4066,"phenoTypeName":"Subcutaneous nodule","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10481,"phenoTypeName":"Abnormality of the eye","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":4782,"phenoTypeName":"Cardiomyopathy","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13734,"phenoTypeName":"Pleuritis","frequencyText":"Very rare","percentRanges":"1%-4%"}],"medicalProducts":[],"EncodedName":"Polyarteritis_nodosa"}